伊立替康联合顺铂用于初治小细胞肺癌的临床观察  

Clinical observation on irinotecan plus cisplatin for first-line treatment of small cell lung cancer

作　　者：赵晓光[1] 宋明霞[1] 徐洁[1] 

机构地区：[1]焦作市人民医院肿瘤内科,河南焦作454002

出　　处：《医药论坛杂志》2013年第4期18-19,22,共3页Journal of Medical Forum

摘　　要：目的观察伊立替康(CPT-11)联合顺铂(DDP)治疗初治小细胞肺癌的临床疗效和安全性。方法 34例小细胞肺癌患者,采用CPT-11 65mg/m2,静滴,第1、8天;DDP 25mg/m2,静滴;第1～3d。21d为1个周期,至少完成2个周期后评价疗效和不良反应。结果 34例患者中CR5例,PR21例,总有效率RR76.5%,无进展生存期(PFS)5.4个月。主要毒副反应为血液学毒性和消化道反应,仅3例出现III度腹泻。结论 CPT-11联合DDP一线治疗小细胞肺癌是安全及有效的,毒性可耐受,迟发性腹泻是可以控制的。Objective To evaluate the efficacy and safety of irinoteean plus cisplatin in the treatment of patients with small cell lung cance（SCLC）. Methods Totally 34 patients with SCLC received irinotecan 65,g/m2 on days1,8, fol- lowed by cisplatin 25 mg/m2 on day 1 -3, and 21 days was one cycle,the evaluation of efficacy and toxicity were performed on all patients after 2 cycles at least. Results Of the 34 patients,5 patients were complete remission （CR） ,21 partial remission （PR）,the total response rate was 76.5% , median progression -free survival （PFS） was 5.4 months, the major toxicities were myelo suppression,gastrointestinal and reaction,only three patients developed grade III diarrhea. Conclusions The combination of irinotecan and cisplatin is effective,and safe for SCLC as frist - line treatment, the toxicitie is tolerable, the delayed diarrhea induced by irinotecan can be controlled by appropriate treatment.

关 键 词：伊立替康 顺铂 小细胞肺癌 

分 类 号：R734.2[医药卫生—肿瘤]